Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
J Renin Angiotensin Aldosterone Syst. 2019 Jul-Sep;20(3):1470320319870891. doi: 10.1177/1470320319870891.
The captopril challenge test (CCT) is the major confirmatory test for primary aldosteronism (PA), and frequently carried out because of its convenience. However, it presents false-negative results with a certain probability, and as there are many criteria for CCT, it is not concluded yet which criteria to use.
A total of 71 PA patients were evaluated. We compared CCT-positive and CCT-negative patients in the following three criteria: plasma aldosterone/renin ratio (ARR) >200 after the CCT (criterion 1); plasma aldosterone concentration (PAC) >120 pg/ml after the CCT (criterion 2); and PAC suppression <30% of PAC before CCT (criterion 3).
The positive rate was 70.4%, 64.8% and 54.9% for criterion 1, criterion 2 and criterion 3, respectively. With criterion 1, the baseline plasma renin activity was lower, thus baseline ARR was higher in CCT-positive patients. With criterion 2, PAC was higher and estimated sodium intake and K were lower in CCT-positive patients. With criterion 3, K and PAC were lower in CCT-positive patients. Although it was not significant, in the patients with high sodium intake, the positive rate of criterion 1 was higher than that of the other criteria.
ARR>200 is the valuable criterion for the diagnosis of PA.
卡托普利激发试验(CCT)是原发性醛固酮增多症(PA)的主要确诊试验,由于其便利性而经常进行。然而,它具有一定的概率呈现假阴性结果,并且由于 CCT 有许多标准,尚未确定使用哪些标准。
共评估了 71 例 PA 患者。我们比较了 CCT 阳性和 CCT 阴性患者在以下三个标准中的情况:CCT 后血浆醛固酮/肾素比值(ARR)>200(标准 1);CCT 后血浆醛固酮浓度(PAC)>120pg/ml(标准 2);和 PAC 抑制< CCT 前 PAC 的 30%(标准 3)。
标准 1、标准 2 和标准 3 的阳性率分别为 70.4%、64.8%和 54.9%。对于标准 1,CCT 阳性患者的基础血浆肾素活性较低,因此基础 ARR 较高。对于标准 2,CCT 阳性患者的 PAC 较高,估计钠摄入量和 K 较低。对于标准 3,CCT 阳性患者的 K 和 PAC 较低。虽然不显著,但在高钠摄入量的患者中,标准 1 的阳性率高于其他标准。
ARR>200 是诊断 PA 的有价值标准。